Distinguished in Leukemia

Krzysztof Kalwak

213 Borowska St, 
Wroclaw, DS, PL 
Distinguished in Leukemia
213 Borowska St, 
Wroclaw, DS, PL 
OverviewLocationsClinical Research

Overview

Krzysztof Kalwak practices in Wroclaw, Poland. Mr. Kalwak is rated as a Distinguished expert by MediFind in the treatment of Leukemia. His top areas of expertise are Nijmegen Breakage Syndrome, Atelosteogenesis Type 1, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Graft.

His clinical research consists of co-authoring 179 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 61 articles and participated in 1 clinical trial in the study of Leukemia.

Gender
Male

Locations

213 Borowska St, Wroclaw, DS 50556, Poland
Other Locations
44 Bujwida St, Wroclaw, DS 50368, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II Study of Blincyto in Children With CD19+ Precursor B-lineage ALL and MRD-Positivity Before and/or Following First Allogeneic HSCT
A Phase II Study of Blincyto in Children With CD19+ Precursor B-lineage ALL and MRD-Positivity Before and/or Following First Allogeneic HSCT
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug
Study Drug: Blinatumomab
Study Phase: Phase 2
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Enrollment Status: Terminated
Publish Date: January 25, 2021
Intervention Type: Other, Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

179 Total Publications

Landscape assessment to characterize baseline access and multilevel barriers to IMProve Access to CAR-T CD19 therapy (IMPACT study) across Europe.
Landscape assessment to characterize baseline access and multilevel barriers to IMProve Access to CAR-T CD19 therapy (IMPACT study) across Europe.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kalwak's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 51 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile